Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

BACKGROUND: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hematol Transfus Cell Ther
Main Authors: Crusoe, Edvan De Queiroz, Higashi, Fabiana, Martinez, Gracia, Bittencourt, Rosane, Pinto Neto, Jorge Vaz, Sousa, Lais, Santucci, Rodrigo, Magalhães, Roberto José Pessoa, Colli, Gilberto, Nunes, Renata Ferreira Marques, Ribeiro, Glaciano, Nicacio, Jandir, Zanella, Karla Richter, Kutner, Jose Mauro, Magalhaes, Andre, Leao, Danielle, Hallack Neto, Abrahão Elias, Braga, Walter, Souza, Emanuella G, Guimaraes, Antonio Julio A.M., Durigon, Giovanna Steffenello, Laks, Dani, Maiolino, Angelo, Hungria, Vania Tietsche de Moraes
Formato: Artigo
Idioma:Inglês
Publicado em: Sociedade Brasileira de Hematologia e Hemoterapia 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248497/
https://ncbi.nlm.nih.gov/pubmed/31537476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.htct.2019.05.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados